IRadimed Q2 Profit Rises on Record Monitor Bookings, Guides Q3 Above Consensus
IRMD sits 70% above its 52-week low of $57.58.
Summary
IRadimed's Q2 earnings beat expectations with adjusted EPS of $0.46 vs. $0.42 consensus, driven by record domestic monitor bookings and the launch of the 3870 MR IV pump. Revenue rose 0.5% to $20.5M, slightly above estimates. Gross margin dipped due to startup costs for the new pump, but management expects improvement as volumes ramp. The company issued Q3 guidance above consensus: revenue of $23.0M-$24.5M and non-GAAP EPS of $0.54-$0.59, and reaffirmed full-year 2026 targets.
At the time of this announcement, IRMD was trading at $97.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $57.58 to $107.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.